Halo Labs, a Burlingame, CA-based life science instrumentation company, raised $6M in Series C funding.
The round was led Agilent Technologies with participation from Research Corporation Technologies, Broad Oak Capital Partners, and BioAdvance.
The company intends to use the funds to continue commercialization of its Aura platform, increasing manufacturing capacity and developing innovative new products to meet the current and new needs of pharmaceutical researchers.
Led by CEO Rick Gordon, Halo Labs is a scientific instrumentation and consumable company that commercializes high throughput aggregate, visible and subvisible particle analysis for biopharmaceutical formulation, stability, and product quality control using custom optics and image processing techniques. Researchers around the globe use it for insights into aggregates and subvisible particles present in their drug products via optical imaging on membranes.
FinSMEs
11/07/2022